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Objective:	Our	 aim	was	 to	define	 the	 incidence	and	outcome	of	AKI	 in	paediatrics	
using	data	collected	from	a	national	electronic	alert	system.		
Design:	 	A	prospective	national	 cohort	 study	was	undertaken	 to	collect	data	on	all	
cases	of	paediatric	AKI,	excluding	neonates,	identified	by	an	e-alert,	from	April	2015	
to	March	2019.	
Results:	 There	were	 2472	 alerts	 in	 a	 total	 of	 1719	patients,	 giving	 an	 incidence	of	
77.3	per	100,000	person-years.	 	84.2%	of	all	AKI	were	stage	1,	and	58.3%	occurred	
with	 a	 triggering	 creatinine	within	 the	 reference	 range.	 	 The	 incidence	 of	 AKI	was	
associated	with	measures	of	social	deprivation.		30-day	mortality	was	1.7%,	but	was	
significantly	higher	 in	HA-AKI	 (2.1%),	 compared	 to	CA-AKI	 (0.8%,	P<0.001)	and	was	
associated	 with	 the	 severity	 of	 AKI	 at	 presentation.	 	 A	 significant	 proportion	 of	
patients	 had	 no	 repeat	measure	 of	 creatinine	 (39.8%).	 	 This	was	 higher	 in	 CA-AKI	
(69.7%)	compared	 to	HA-AKI	 (43.0%,	P<0.001),	and	higher	 in	patients	alerting	with	
patients	 triggering	with	 a	 creatinine	within	 the	 reference	 range	 (48.4%	 vs.	 24.5%,	
P<0.001).	 	 The	 majority	 of	 patients	 (84.7%)	 experienced	 only	 one	 AKI	 episode.		
Repeated	 episodes	 of	 AKI	 were	 associated	 with	 increased	 30-mortaltiy	 (11.6%	 vs.	
4.6%,	P<0.001)	and	higher	residual	renal	impairment	(13.3%	vs.	5.4%,	p<0.001).			
Conclusions	The	results	suggest	that	the	significance	of	the	alert	 is	missed	in	many	














,	 long	 term	 renal	 dysfunction	
3
.	 	 Using	 a	 centralised	 system	 of	 data	
collection,	 based	 on	 an	 electronic	 AKI	 alert,	 we	 have	 published	 a	 detailed	
characterisation	of	 the	 epidemiology	 of	AKI	 in	 adults	
4-11
.	 	 	Our	 previous	 data	 in	 a	









AKI	 e-alert	 between	 April	 2015	 and	 March	 2019.	 Patients	 aged	 ≤28	 days	 were	
excluded.	 The	 study	 was	 approved	 under	 the	 terms	 of	 Service	 Evaluation	 Project	
Registration.			
The	 Welsh	 electronic	 AKI	 reporting	 system	
4
	 utilises	 the	 all	 Wales	 Laboratory	
Information	Management	 System	 (LIMS),	 (InterSystems	 TrakCare	 Lab)	 to	 compare	
measured	serum	creatinine	(SCr)	values	on	an	individual	against	previous	results	for	
the	 same	 patient,	 in	 real	 time,	 to	 generate	 alerts	 using	 an	 algorithm	 based	 on	





creatinine	 and	 stage	 3	 AKI	 ≥	 3	 times	 the	 reference	 creatinine or	 a	 rise	 of	 ≥1.5	
baseline	to	>	354mmol/l.			AKI	alerts	are	generated	by	applying	three	“rules”	based	







done	 in	Wales,	 regardless	 of	 the	 patient	 location	 and	 the	 ordering	 clinician.	 	 The	
alert	is	transmitted	with	the	result	of	the	serum	creatinine	as	a	‘flag”	that	states	that	
the	result	 is	abnormal	and	 in	keeping	with	AKI.	 	The	AKI	stage	 is	also	reported	and	
the	 alert	 signposts	 the	 reviewing	 clinician	 to	 	 the	Welsh	 AKI	 clinical	 management	
guidelines.	 	 	 Creatinine	 is	measured	 using	 kinetic	 Jaffe	methodology,	 standardised	
using	ID/MS	calibrated	reference	material.	
Result	of	renal	transplant	and	dialysis	patients,	and	alerts	generated	in	renal	wards	




Hospital	acquired	 (HA-AKI)	was	defined	as	AKI	 triggered	by	an	alert	 in	an	 inpatient	
















baseline	SCr	 (bSCr)	value	which	generated	the	alert.	 	Patients	were	 included	 in	30-
day	 renal	 outcome	 analysis	 if	 they	 survived	 the	 episode	 and	 had	 follow	 up	 data	




of	 1,909	 geographical	 areas	 in	 Wales,	 based	 on	 Income,	 Employment,	 Health,	
Education,	Access	to	Services,	Community	Safety,	Physical	Environment,	Housing	to	
generate	 a	 WIMD	 score	
15







Statistical	 analysis	 was	 carried	 out	 using	 SPSS	 software,	 version	 20	 (SPSS,	 Inc.,	















30-day	 mortality	 was	 1.7%	 (Table5	 )	 and	 overall	 mortality	 was	 5.67%.	 Higher	


























was	 highest	 following	 an	 A+E	 alert	 (40.5%).	 There	was	 no	 difference	 in	 admission	
rates	 following	 OPD	 or	 GP	 alerts	 (14.0	 vs.	 7.1%,	 P>0.05).	 It	 is	 of	 note	 that	 all	 9	
patients	admitted	following	a	GP	alert,	presented	with	a	stage	1	AKI	alert,	whilst	12	












The	majority	of	patients	 (84.7%)	generated	only	one	AKI	alert.	 	Of	 those	 triggering	















of	AKI	alerts	 in	 this	paediatric	population	occurs	with	a	creatinine	value	within	 the	
reference	range.	There	was	no	difference	in	age	between	the	two	groups	(Table	8),	
but	 as	 expected	 alerts	 with	 creatinine	 values	 above	 the	 reference	 range	 included	
more	stage	2	or	3	AKI,	than	those	alerting	with	a	normal	creatinine	(27.6%	vs.	7.9%,	
 9 
P<0.001).	 92	 patients	 experienced	AKI	 stage	 2/3	with	 an	 alerting	 serum	 creatinine	
within	 the	 estimated	 reference	 range.	 	 	 An	 alert	 with	 a	 creatinine	 above	 the	
estimated	reference	range	was	more	common	in	HA-AKI	compared	to	CA-AKI	(64.1%	
vs.	35.9%,	p<0.01).		In	the	CA-AKI	patients,	those	alerting	with	a	creatinine	above	the	
reference	 range	 were	 more	 likely	 to	 be	 admitted	 to	 hospital	 than	 those	 alerting	
within	the	estimated	normal	creatinine	range	(34.1%	vs.	12.4%,	p<0.001).		
30-day	mortality	was	higher	in	the	abnormal	creatinine	alert	cohort	(3.1%	vs.	0.9%,	
P<0.001),	similarly	mortality	censored	at	4	years	 (Figure	2D)	was	also	higher	 in	 the	





up	measure	of	 renal	 function	within	30	days,	was	more	 likely	 for	patients	with	 an	
alert	outside	of	the	reference	range	(75.5%	vs.	51.6%,	P<0.001),	although	it	is	of	note	
that	 even	 in	 this	 cohort	 a	 significant	 proportion	 (24.5%)	 had	 no	 follow	 up	
measurement.			
Discussion	








Whilst	 the	 epidemiology	 of	 adult	 AKI	 is	 well	 described,	 there	 are	 few	 published		











.	 To	 our	 knowledge	 the	 current	 manuscript	 reflects	 a	
characterisation	 of	 the	 largest	 cohort	 of	 paediatric,	 non-neonatal,	 AKI	 reported	 to	
date.			




coding	 and	 a	 focus	 on	 hospitalised	 cases.	 	 As	 expected	 for	 the	 whole	 cohort	 the	
outcomes	 following	 AKI	 both	 mortality	 and	 non-recovery	 of	 renal	 function	 are	
related	to	the	severity	of	the	AKI	at	presentation.		It	is	of	note	that	a	large	cohort	of	
patients	 for	whom	an	AKI	 alert	 is	 transmitted,	 including	patients	with	 stage	 2	 and	
stage	3	AKI,	had	no	repeat	measure	of	creatinine.	 	This	reflects	at	 least	 in	part	 the	
lower	number	of	blood	tests	undertaken	 in	children	compared	to	adults.	 	A	 recent	










higher	 burden	 of	 co-morbidities.	 	 In	 contrast,	 in	 paediatric	 populations	 previous	
studies	 in	 non-renal	 illnesses	 suggest	 that	 social	 inequality	 likely	 reflect	










other	primary	 illnesses	which	 lead	 to	 reduced	 renal	perfusion.	 	 It	 is	 likely	 that	 it	 is	
alterations	 in	 the	 patterns	 of	 common	 causes/precipitants	 of	 AKI	 that	 therefore	
underpin	 the	 associations	 between	 socio-economic	 deprivation	 and	 the	 increased	
incidence	of	AKI	in	children.	It	is	also	of	note	that	most	children	need	to	rely	on	adult	





hospitalized-acquired	AKI	 tended	 to	be	 younger	 and	boys,	without	 clinical	 data	on	
the	associated	diagnoses,	any	explanation	of	this	remains	speculative.  In	contrast	to	
the	higher	mortality	in	the	HA-AKI	group,	recovery	of	renal	function	in	those	patients	





for	 those	 who	 do	 have	 a	 repeat	 measure	 than	 HA-AKI.	 Previously	 we	 have	








the	 episode	 may	 be	 related	 to	 either	 the	 illness	 precipitating	 the	 hospital	
consultation	 and	 measure	 of	 renal	 function	 or	 changes	 made	 in	 response	 to	 the	

















.	 	 In	contrast	 less	than	5%	of	the	paediatric	population	have	pre-






creatinine	above	the	reference	range.	 	 It	 is	of	note	that	cases	of	stage	2	and	3	AKI	







repeat	 blood	 test	 the	 time	 to	 repeat	was	 significantly	 longer	 in	 the	 group	 alerting	
with	 a	 creatinine	 in	 the	 reference	 range.	 	 Previous	 published	 data	 have	






significance	of	 increases	 in	 serum	creatinine	when	 they	occur	within	 the	 reference	
range,	even	when	highlighted	with	an	AKI	alert	may	not	be	appreciated,	and	that	this	
may	 lead	 to	 missed	 opportunities	 for	 early	 intervention	 to	 improve	 clinical	
outcomes.		
This	study	is	to	our	knowledge	the	first	national	study	using	an	e-alert	based	system	
to	 describe	 the	 epidemiology	 of	 AKI	 in	 children,	 however	 its	 findings	 should	 be	
qualified	 by	 its	 limitations.	 	 As	 the	 e-alert	 system	 is	 IT	 driven	 and	 is	 based	 on	






but	with	presenting	with	a	 raised	creatinine	will	not	be	 included.	 	Given	 that	most	
children	never	have	a	serum	creatinine	checked	during	their	childhood,	the	pediatric	







have	 limitations	 in	 those	 children	 in	which	 there	 are	 clinical	 reasons	 (for	 instance	
myopathies	 or	 chronic	 illness	 with	 poor	 nutrition)	may	 have	 a	 substantially	 lower	
serum	creatinine	than	normal.	Although	this	is	likely	to	represent	a	small	number	of	
children,	 it	 may	 also	 result	 in	 an	 underestimation	 of	 AKI	 rates	 in	 out	 study.	





In	 conclusion,	 the	 manuscript	 describes	 the	 epidemiology	 of	 AKI	 when	 identified	
through	 an	 electronic	 AKI	 alert.	 	 It	 highlights	 a	 higher	 incidence	 than	 previously	
reported	 and	 demonstrates	 that	 a	 large	 number	 of	 patient	 have	 no	 follow	 up	
measurement	 of	 renal	 function	 following	 an	 AKI	 alert.	 This	 suggests	 that	 the	
significance	of	 the	alert	may	be	missed.	This	may	reflect	 that	a	 large	proportion	of	
electronic	alerts	reported	AKI	triggered	by	a	rise	in	serum	creatinine	which	lie	within	
the	normal	range.		These	may	therefore	be	interpreted	as	being	insignificant	despite	
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Table 1.  Staging of AKI 
Stage Serum creatinine 
1 1.5 -1.9 times baseline or ≥26µmol/L increase 
2 2.0-2.9 times baseline  
3 3.0 times baseline or ≥354µmol/L 
 
Table 2.  E-alert rules.  
Rule Description Associated alert 
1 >26µmol/L increase in creatinine in 
previous 48 hours 
Acute Kidney Injury alert: rising 
creatinine within last 48 hours 
2 >50% increase in creatinine in 
previous 7 days 
Acute Kidney Injury alert: rising 
creatinine within last 7 days 
3 >50% increase in creatinine against 
median result for previous 8-365 days 
Acute Kidney Injury alert – 
creatinine increase over baseline 
value 
   
 
 






DELTA1 D>26µmol/L and no other rule triggered 1 1 
ABS1 C1/RV1>C1/RV2 and C1/RV1≥1.5 and 
C1>354µmol/L 
2 3 
ABS2 C1/RV2>C1/RV1 and C1/RV2≥1.5 and 
C1>354µmol/L 
3 3 
R1AKI1 C1/RV1>C1/RV2 and C1/RV1≥1.5 and C1/RV1<2.0 2 1 
R1AKI2 C1/RV1>C1/RV2 and C1/RV1≥2.0 and C1/RV1<3.0 2 2 
R1AKI3 C1/RV1>C1/RV2 and C1/RV1≥3.0 2 3 
R2AKI1 C1/RV2>C1/RV1 and C1/RV2≥1.5 and C1/RV2<2.0 3 1 
R2AKI2 C1/RV2>C1/RV1 and C1/RV2≥2.0 and C1/RV2<3.0 3 2 
R2AKI3 C1/RV2>C1/RV1 and C1/RV2≥3.0 3 3 
D, Difference between C1 and lowest previous serum creatinine (SCr) value within 48 hours; 
C1, Index SCr value (current result entered and authorised on the LIMS); RV1, Reference 
value 1, lowest SCr value existing within previous 7 days; RV2, Reference value 2, median 








Table 4: Serum Creatinine reference ranges for age and sex	
Age	(yrs)	 Sex	 Lower	(µmol/l)	 Upper (µmol/l)	
0-1	 M/F	 15.03	 37.13	
1-4	 M/F	 16.80	 43.32	
5-9	 M/F	 22.98	 53.92	
10-14	 M/F	 30.94	 76.02	
15-17	 M		 38.90	 97.24	




 Table 5: Characteristics of the paediatric cohort 
Variable Whole cohort HA CA P value  
HA vs. CA 
Number of episodes, n (% of whole cohort) 2472 (100) 1719 (69.5) 753 (30.5) P<0.001 
Number of patients, n (%) 1942 (100) 1323 (68.1) 619 (31.9) P<0.001 
Mean (Median) age ±SD (years) 7.3 (5) ±6.1 6.3 (5) ±5.7 9.4 (10) ±6.3 P<0.001 
Male, n (%) 1003 (51.6) 729 (55.1) 724 (44.3) P<0.001 
Pre-existing CKD, n (%) 74 (3.8) 54 (4.1) 20 (3.2) P=n/s 
AKI stage 1, n (%) 1635 (84.2) 1118 (84.5) 517 (83.5) P=n/s 
AKI stage 2, n (%) 238 (12.3) 157 (11.9) 81 (13.1) P=n/s 
AKI stage 3, n (%) 69 (3.6) 48 (3.6) 21 (3.4) P=n/s 
Admitted to hospital, n (%)   137 (22.1) 
 
Repeat test within 30 days, n (%) 1188 (61.2) 922 (69.7) 266 (43.0) P<0.001 
Mean time to repeat ±SD (days) 2.9 ±5.3 2.7 ±5.0 3.4 ±6.0 P<0.01 
30-day mortality, n (%) 33 (1.7) 28 (2.1) 5 (0.8) P<0.05 
30-day recovery, n (%) 1010 (94.0) 795 (95.0) 215 (90.7) P<0.05 
Mean time to 30-day recovery ±SD (days) 4.1 ±6.4 4.0 ±6.2 4.5 ±7.0 P=n/s 
1,868 patients (1,281, HA; 587, CA) were included in analysis of the 30-day mortality variable. 1,074 patients (837, HA; 237, CA) were included in analysis 
of the 30-day recovery variable. HA, hospital acquired AKI; CA, community acquired AKI; CKD, Chronic Kidney Disease. The index episode was used for 
patients with multiple episodes of AKI. 
 
	
Table 6: Characteristics of the community acquired AKI paediatric cohort 
Variable AE OP GP P value  
AE vs. OP 
P value  
AE vs. GP 
P value  
OP vs. GP 
Number of episodes, n (% of CA-AKI) 257 (34.1) 250 (33.2) 141 (18.7) P=n/s P<0.001 P<0.001 
Number of patients, n (% of CA-AKI) 222 (35.9) 193 (31.2) 127 (20.5) P=n/s P<0.001 P<0.001 
Mean age ±SD (years) 12.3 ±5.7 6.7 ±5.8 9.7 ±6.0 P<0.001 P<0.001 P<0.001 
 
AKI stage 1, n (%) 170 (76.6) 166 (86.0) 115 (90.6) P<0.05 P<0.01 P=n/s 
AKI stage 2/3, n (%) 52 (23.4) 27 (14.0) 12 (9.5) P<0.05 P<0.01 P=n/s 
30-day mortality, n (%) 4 (1.9) 0 (0.0) 0 (0.0) P=n/s P=n/s 
 
30-day recovery, n (%) 116 (88.6) 56 (93.3) 22 (91.7) P=n/s P=n/s P=n/s 
Mean time to 30-day recovery ±SD (days) 2.6 ±5.3 5.3 ±7.8 9.7 ±7.1 P<0.001 P<0.001 P=n/s 
Repeat test within 30 days, n (%) 147 (66.2) 62 (32.1) 27 (21.3) P<0.001 P<0.001 P<0.05 
Average time to repeat ±SD (days) 1.9 ±5.1 4.5 ±7.0 7.6 ±5.9 7.92E-07 P<0.001 P=n/s 
Admitted to hospital, n (%) 90 (40.5) 27 (14.0) 9 (7.1) P<0.001 P<0.001 P=n/s 
Admitted stage 1, n (%) 61 (35.9) 20 (12.1) 9 (7.8) P<0.001 P<0.001 P=n/s 
Admitted stage 2/3, n (%) 29 (55.8) 7 (25.9) 0 (0.0) P<0.05 P<0.001 P=n/s 
Repeat test within 30 days for admitted stage 2/3, n 
(%) 
41 (78.9) 12 (44.4) 1 (8.3) P<0.01 P<0.001 P<0.05 
522 patients (207, AE; 191, OP; 124, GP) were included in analysis of the 30-day mortality variable. 215 patients (131, AE; 60, OP; 24, GP) were included 
in analysis of the 30-day recovery variable. AE, Accident & Emergency; OP, Out Patient; GP, General Practice.  The index episode was used for patients 
with multiple episodes of AKI. 
Table 7: Characteristics of patients who had a single episode of AKI vs. patients who had recurrent 
episodes of AKI 
Variable One episode Recurrent 
episodes 
P value 
Number of patients, n (% of whole cohort) 1645 (84.7) 297 (15.3) 
 
Mean (Median) age ±SD (years) 7.4 (6) ±6.1 6.7 (5) ±5.1 P=n/s 
AKI stage 1, n (%) 1391 (84.1) 244 (82.2) P=n/s 
AKI stage 2/3, n (%) 254 (15.4) 53 (17.9) P=n/s 
Hospital acquired, n (%) 1104 (67.1) 219 (73.7) P<0.05* 
Community acquired, n (%) 541 (32.9) 78 (26.3) P<0.05* 
Overall mortality, n (%) 73 (4.6) 33 (11.6) P<0.001 
Overall recovery, n (%) 807 (94.5) 183 (86.7) P<0.001 
Mean time to overall recovery ±SD (days) 3.8 ±5.9 5.4 ±8.0 P<0.001 
Repeat test within 30 days, n (%) 950 (57.8) 238 (80.1) P<0.001 
Mean time to repeat ±SD (days) 2.6 ±4.8 3.9 ±6.8 P<0.001 
Mean number of episodes ±SD (range) 
 
2.8 ±1.4 (2-11) 
 
1,868 patients (1,583, One episode; 285, Recurrent episodes) were included in analysis of the overall 
mortality variable. 1,065 patients (854, One episode; 211, Recurrent episodes) were included in 
analysis of the overall recovery variable. *P value is for comparison of hospital acquired vs. 
community acquired for the ‘Recurrent episodes’ group. The index episode was used for patients 
with multiple episodes of AKI. 
 
Table 8: Characteristics of episodes generated by an AKI e-alert triggered by a creatinine value 
within the reference range vs. episodes generated by an AKI e-alert triggered by a creatinine value 
above the reference range 
Variable Alert SCr  
in RR 
Alert SCr  
above RR 
P value 
Number of episodes, n (% of whole cohort) 1441 (58.3) 1031 (41.7) P<0.001 
Number of patients, n (% of whole cohort) 1164 (59.9) 778 (40.1) P<0.001 
Mean (Median) age ±SD (years) 6.6 (5) ±6.1 8.3 (7) ±6.0 P<0.001 
AKI stage 1, n (%) 1072 (92.1) 563 (72.4) P<0.001 
AKI stage 2/3, n (%) 92 (7.9) 215 (27.6) P<0.001 
Hospital acquired, n (%) 824 (70.8) 499 (64.1) P<0.01* 
Community acquired, n (%) 340 (29.2) 279 (35.9) P<0.01* 
30-day mortality, n (%) 10 (0.9) 23 (3.1) P<0.001 
30-day recovery, n (%) 532 (96.7) 478 (91.2) P<0.001 
Mean time to 30-day recovery ±SD (days) 4.2 ±6.3 4.0 ±6.5 P<0.01 
Repeat test within 30 days, n (%) 601 (51.6) 587 (75.5) P<0.001 
Mean time to repeat ±SD (days) 3.4 ±5.7 2.3 ±4.8 P<0.001 
1,868 patients (1,128, Alert SCr in reference range; 740, Alert SCr above reference range) were 
included in analysis of the 30-day mortality variable. 1,074 patients (550, Alert SCr in reference 
range; 524, Alert SCr above reference range) were included in analysis of the 30-day recovery 
variable. SCr, Serum Creatinine; RR, Reference range. *P value is for comparison of hospital 
acquired vs. community acquired for both groups. The index episode was used for patients with 
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r=-0.91,	95%	CI	-0.94	to	-0.87	p<0.001		
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